Immunocore (IMCR) Competitors $30.15 +0.05 (+0.17%) Closing price 04:00 PM EasternExtended Trading$30.08 -0.07 (-0.25%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. TGTX, TLX, BPMC, SRPT, AXSM, NUVL, VRNA, GRFS, KRYS, and ADMAShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Verona Pharma Grifols Krystal Biotech ADMA Biologics TG Therapeutics (NASDAQ:TGTX) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Do insiders and institutionals believe in TGTX or IMCR? 58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 10.5% of TG Therapeutics shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor TGTX or IMCR? In the previous week, TG Therapeutics had 9 more articles in the media than Immunocore. MarketBeat recorded 17 mentions for TG Therapeutics and 8 mentions for Immunocore. TG Therapeutics' average media sentiment score of 1.34 beat Immunocore's score of 1.30 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TGTX or IMCR? TG Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Does the MarketBeat Community favor TGTX or IMCR? TG Therapeutics received 587 more outperform votes than Immunocore when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 73.47% of users gave Immunocore an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% ImmunocoreOutperform Votes7273.47% Underperform Votes2626.53% Is TGTX or IMCR more profitable? TG Therapeutics has a net margin of -5.42% compared to Immunocore's net margin of -15.87%. TG Therapeutics' return on equity of -8.32% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics-5.42% -8.32% -3.40% Immunocore -15.87%-12.84%-5.09% Which has stronger valuation & earnings, TGTX or IMCR? TG Therapeutics has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329.00M21.90$12.67M$0.14324.07Immunocore$310.20M4.87-$55.29M-$1.02-29.56 Do analysts rate TGTX or IMCR? TG Therapeutics currently has a consensus price target of $40.67, suggesting a potential downside of 10.37%. Immunocore has a consensus price target of $59.44, suggesting a potential upside of 97.16%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Immunocore 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45 SummaryTG Therapeutics beats Immunocore on 14 of the 18 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.51B$2.96B$5.49B$7.95BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-31.7430.2822.6218.58Price / Sales4.87496.13397.85103.49Price / CashN/A168.6838.1834.62Price / Book4.063.176.744.25Net Income-$55.29M-$72.35M$3.22B$248.18M7 Day Performance-0.69%0.96%1.59%1.36%1 Month Performance5.31%8.29%4.09%3.85%1 Year Performance-48.94%-22.57%15.98%5.37% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore3.1875 of 5 stars$30.15+0.2%$59.44+97.2%-49.1%$1.51B$310.20M-31.74320Upcoming EarningsNews CoveragePositive NewsTGTXTG Therapeutics3.3177 of 5 stars$36.97-3.5%$40.67+10.0%+233.2%$5.81B$329.00M-369.66290Upcoming EarningsNews CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.5644 of 5 stars$84.18-0.6%$124.95+48.4%-2.0%$5.38B$508.82M-77.94640Earnings ReportAnalyst ForecastNews CoverageSRPTSarepta Therapeutics4.7356 of 5 stars$55.23+2.7%$158.70+187.3%-50.7%$5.36B$1.90B44.18840Upcoming EarningsAXSMAxsome Therapeutics4.8404 of 5 stars$103.00-1.4%$169.80+64.9%+52.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsNUVLNuvalent1.887 of 5 stars$69.95-2.4%$115.50+65.1%+11.4%$5.01BN/A-20.1640Upcoming EarningsPositive NewsVRNAVerona Pharma2.9022 of 5 stars$60.07+2.0%$75.43+25.6%+366.5%$4.85B$42.28M-31.2930Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsGRFSGrifols3.9001 of 5 stars$7.01-1.0%N/A+8.1%$4.82B$7.21B5.9926,300KRYSKrystal Biotech4.9107 of 5 stars$161.91-4.0%$220.00+35.9%+10.9%$4.68B$290.52M54.15210Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsADMAADMA Biologics1.4608 of 5 stars$19.64-7.8%$22.50+14.6%+265.0%$4.64B$426.45M70.14530Upcoming EarningsOptions VolumeNews CoveragePositive News Related Companies and Tools Related Companies TGTX Competitors TLX Competitors BPMC Competitors SRPT Competitors AXSM Competitors NUVL Competitors VRNA Competitors GRFS Competitors KRYS Competitors ADMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMCR Stock Free IMCR Stock Alerts